07:28 AM EDT, 10/28/2024 (MT Newswires) -- Eli Lilly ( LLY ) said Monday that phase 3 studies of its drug mirikizumab showed sustained stable, long-term remission in patients across two inflammatory bowel diseases, ulcerative colitis and Crohn's disease.

One study showed that mirikizumab helped 81% of patients with moderately to severely active ulcerative colitis to maintain long-term clinical remission, the company said.

It added that new data from a long-term extension study showed that patients with moderately to severely active Crohn's disease treated with mirikizumab maintained 87% clinical remission as measured by the Crohn's Disease Activity Index and 76% endoscopic response over time, respectively.

Mirikizumab is already approved in the US for treating moderately to severely active ulcerative colitis in adults and is currently under FDA review for Crohn's disease.

Price: 897.26, Change: +4.56, Percent Change: +0.51